Region Stockholm

FRIDAY, Jan. 3, 2025 -- AI can outperform human doctors when it comes to identifying ovarian cancer from ultrasound images. A new study published in the journal Nature Medicine shows that specially trained AI program achieved an accuracy rate of more than 86% in identifying ovarian cancer by scanning ultrasounds, compared to just under 83% for human experts and nearly 78% for non-expert examiners. “Ovarian tumors are common and are often detected by chance,” researcher Elisabeth Epstein , a senior physician with the Stockholm South General Hospital’s Department of Clinical Science and Education, said in a news release from the Karolinska Institute in Sweden. These results suggest that AI “can offer valuable support in the diagnosis of ovarian cancer, especially in difficult-to-diagnose cases and in settings where there’s a shortage of ultrasound experts,” Epstein said. For the study, researchers trained an AI program to be able to tell the difference between benign and malignant ovarian lesions, using more than 17,000 ultrasound images from nearly 3,700 patients across 20 hospitals in eight countries. The AI program also cut back on the need for expert referrals, by backing up human doctors, researchers found. In a simulated care scenario, support from the AI cut the number of referrals by 63% and the misdiagnosis rate by 18%. Overall, these results show that AI could contribute to faster and more cost-effective care for patients with ovarian lesions, researchers concluded. However, the research team noted that more studies are needed to validate their findings and fully explore the potential helpfulness of AI. They are now conducting research to evaluate the everyday clinical safety and usefulness of the program, and are planning for a clinical trial to examine the AI’s effect on patient management and health care costs. “With continued research and development, AI-based tools can be an integral part of tomorrow’s healthcare, relieving experts and optimizing hospital resources, but we need to make sure that they can be adapted to different clinical environments and patient groups,” co-lead researcher Filip Christiansen , a doctoral student in Epstein’s research group at Karolinska Institute, said in a news release. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

NEW YORK, March 31, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of SOS Limited (“SOS” or the “Company”) (NYSE: SOS) from July 22, 2020, through February 25, 2021 (the “Class Period”). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit SOS Shareholder Class Action Lawsuit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com The complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements, as well as failed to disclose to investors: (i) SOS had misrepresented the true nature, location, and/or existence of at least one of the principal executive offices listed in its SEC filings; (ii) HY and FXK were either undisclosed related parties and/or entities fabricated by the Company; (iii) the Company had misrepresented the type and/or existence of the mining rigs that it claimed to have purchased; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. On February 26, 2021 Hindenburg Research (“Hindenburg”) and Culper Research (“Culper”) released commentary on SOS, claiming that the Company was an intricate “pump and dump” scheme that used fake addresses and doctored photos of crypto rigs to create an illusion of success. On this news, SOS’s American depositary share (“ADS”) price fell $1.27 per share, or 21.03%, to close at $4.77 per ADS on February 26, 2021. If you wish to serve as lead plaintiff, you must move the Court no later than June 1, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. If you purchased SOS securities, and/or would like to discuss your legal rights and options please visit or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for ten consecutive years. ATTORNEY ADVERTISING. © 2021 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information Matthew E. Guarnero Bernstein Liebhard LLP (877) 779-1414 MGuarnero@bernlieb.com

SHANGHAI, March 25, 2020 /PRNewswire/ -- China Rapid Finance Limited (NYSE: XRF) today announced it has reached a non-binding letter of intent on investment and cooperation with SOS Health Rescue Services Ltd. ("SOS"). Subject to due diligence and other conditions, the parties may enter into a merger or similar transaction in which SOS or its stockholders will own a controlling interest of the outstanding equity in XRF. The transaction is subject to numerous conditions and there is of course no assurance that such a transaction will be consummated on the terms and timeline indicated. This merger, if completed, will allow XRF to enter the new and growing area of consumer health services and health care related financial services. XRF and SOS are targeting the signing of the initial agreement by end of March 2020. About China Rapid Finance China Rapid Finance (NYSE: XRF) is a fintech company that offers technology solutions for decision makers and related marketing services that addresses China's growing consumer credit market. The Company utilizes its proprietary technology and 18 years of experience to provide its services. The Company is establishing partnerships and is currently developing strategic alternatives and new businesses in financial technology, marketing services and loan portfolio management. For more information, please visit . About SOS Health Rescue Services Ltd. SOS Health Rescue Services Ltd is one of the largest health rescue services providers in China. It offers the equivalent of a private 911 call service for emergencies. Through its cloud based technologies and nationwide call centers, it works closely with hospitals, insurance companies, large corporations, nursing homes, police and communities to provide health related emergency transportation and rescue on demand services. View original content: Related Links :